

1 **Title:**

2 **Factors associated with human papillomavirus, hepatitis A, hepatitis B and**
3 **mpox vaccination uptake among gay, bisexual and other men who have sex**
4 **with men in the UK – findings from the large community-based RiISH-Mpox**
5 **survey**

6
7 **Authors:**

8 George Baldry (george.baldry@ukhsa.gov.uk) ^{1,2}
9 Dawn Phillips ¹ (dawn.phillips@ukhsa.gov.uk)
10 Ruth Wilkie ¹ (ruth.wilkie@ukhsa.gov.uk)
11 Marta Checchi ¹ (marta.checchi@ukhsa.gov.uk)
12 Kate Folkard ¹ (kate.folkard@ukhsa.gov.uk)
13 Ruth Simmons ¹ (ruth.simmons@ukhsa.gov.uk)
14 John Saunders ^{1,2,3} (john.saunders@ukhsa.gov.uk)
15 Sema Mandal ¹ (sema.mandal@ukhsa.gov.uk)
16 Catherine H Mercer ^{2,3} (c.mercer@ucl.ac.uk)
17 Hamish Mohammed ^{1,2,3} (hamish.mohammed@ukhsa.gov.uk)
18 Dana Ogaz ^{1,3} (dana.ogaz@ukhsa.gov.uk)

19
20 **Affiliations:**

21 ¹ Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, United
22 Kingdom
23 ² Institute for Global Health, University College London, London, United
24 Kingdom
25 ³ The National Institute for Health and Care Research Health Protection Research Unit in
26 Blood Borne and Sexually Transmitted Infections at University College London in
27 partnership with the UK Health Security Agency, London, United Kingdom

28
29 **Word count:** (2848/3000)

30
31 **Key words:** Mpox, Viral Hepatitis, HPV, Vaccine Uptake, GBMSM, UK
32

33 **Abstract (249/250)**

34
35 **Background:** Gay, bisexual, and other men who have sex with men (GBMSM) face a
36 disproportionate burden of sexually transmitted infections and are eligible for targeted
37 vaccinations for hepatitis A (HAV), hepatitis B (HBV), human papilloma virus (HPV) and
38 mpox. This study examines the sociodemographic characteristics, sexual behaviours, and
39 sexual healthcare service (SHS) use associated with vaccination uptake.

40 **Methods:** We undertook analyses of RiISH-Mpox - an online, community-based survey with
41 GBMSM recruited via social media and dating apps. We calculated vaccination uptake (≥ 1

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

42 dose) among eligible GBMSM. Bivariate and multivariable logistic regression was performed
43 to identify factors independently associated with vaccination uptake among eligible
44 participants.

45 **Results:** Reported uptake in eligible GBMSM was around two-thirds for each of the
46 vaccinations considered: mpox 69% (95% confidence interval (CI): 66%-72%), HAV 68%
47 (CI:65%-70%), HBV 72% (CI:69%-74%) and HPV 65% (CI:61%-68%). Vaccination course
48 completion (receiving all recommended doses) ranged from 75% (HBV) to 89% (HAV)
49 among eligible GBMSM. Individuals who represented missed opportunities for vaccination
50 ranged from 22-30% of eligible SHS attendees. Younger participants, individuals identifying
51 as bisexual, reporting lower educational qualifications, or being unemployed reported lower
52 uptake across GBMSM-selective vaccinations. Individuals who reported greater levels of
53 sexual behaviour and recent SHS use were more likely to report vaccinations.

54 **Conclusion:** Eligible participants reported high uptake of vaccinations; however, uptake was
55 lower amongst young GBMSM and self-identifying bisexual men. Awareness of groups with
56 lower vaccination uptake will help inform practice, delivery strategies and health promotion,
57 to improve the reach and impact of vaccinations amongst GBMSM.

58 **Contributions:**

59 DP, RW, KF, CHM, JS, HM reviewed and updated the survey instrument. Survey
60 implementation, data collection and data management were carried out by RW and DO. GB,
61 CM, DO, HM curated secondary analysis plan with review and contributions from KF, MC,
62 JS, RS, SM. GB conducted analysis and completed the first manuscript draft. All authors
63 contributed to successive drafts and reviewed and approved the final manuscript.

64 **Ethics statement:**

65 Ethical approval of this study was provided by the UKHSA Research and Ethics Governance
66 Group (REGG; ref: R&D 524). Online informed consent was received from all participants
67 and all methods were performed in accordance with guidelines and regulations set by the
68 UKHSA REGG.

69 **Competing interests:**

70 Authors have no competing interests to declare.

71 **Data availability statement:**

72 The data that support the findings of this study are available upon reasonable request from the
73 UK Health Security Agency (UKHSA). Requests can be directed to Dr Hamish Mohammed
74 (hamish.mohammed@ukhsa.gov.uk).

75 **Funding:**

76 This study did not receive any funding and was conducted as part of the UKHSA public
77 health response to mpox.

78 **Acknowledgements:**

79 The authors wish to thank all the participants who took part in this study. We acknowledge
80 members of the National Institute for Health and Care Research Health Protection Research
81 Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted Infections (BBSTI) Steering
82 Committee: Professor Caroline Sabin (HPRU Director), Dr John Saunders (UK Health
83 Security Agency Lead), Professor Catherine Mercer, Dr Hamish Mohammed (previously
84 Professor Gwenda Hughes), Professor Greta Rait, Dr Ruth Simmons, Professor William
85 Rosenberg, Dr Tamyo Mbisa, Professor Rosalind Raine, Dr Sema Mandal, Dr Rosamund
86 Yu, Dr Samreen Ijaz, Dr Fabiana Lorencatto, Dr Rachel Hunter, Dr Kirsty Foster and Dr
87 Mamooma Tahir. The authors would also like to thank Takudzwa Mukiwa (Terrence Higgins
88 Trust) and Will Nutland (The Love Tank) for their review of the mpox module in the RiiSH-
89 Mpox survey used for this research.

90

91

92

93 **Introduction**

94
95

96 Gay, bisexual, and other men who have sex with men (GBMSM) continue to be
97 disproportionately affected by sexually transmitted infections (STIs) and viral hepatitis
98 (VHs) both globally¹ and in the UK². To reduce individual and public health impacts of these
99 infections in the UK, several vaccines are recommended for GBMSM³⁻⁶, this includes HPV
100 (human papilloma virus), Hepatitis A (HAV) and Hepatitis B (HBV), which can be spread
101 through sexual contact amongst other means⁷.

102

103 UK immunisation policy and clinical advice is outlined in The Green Book: Immunisation
104 against Infectious Disease, a compilation of immunisation evidence, procedures, and
105 guidance for vaccine preventable diseases⁸. The UK currently recommends opportunistic
106 immunisation against HAV and HBV to all GBMSM, particularly those who change sexual
107 partners frequently^{3,7}. HPV vaccination in the UK was initially introduced for girls aged 12-
108 13 to prevent cervical cancer⁹, but was recommended for GBMSM up to and including age 45
109 from 2016 and for adolescent boys from 2019⁵. Most recently, GBMSM-selective
110 vaccination programmes have been brought into focus through the rapid introduction of
111 vaccination for mpox in response to the 2022 mpox outbreak which particularly affected this
112 group¹⁰.

113

114 There is limited literature examining STI/VH vaccination uptake and acceptability among
115 GBMSM. While a pilot study among UK GBMSM found that 89% would willingly receive
116 the HPV vaccine upon recommendation¹¹, reported uptake of the HPV vaccine is only 34%
117 among GBMSM attending sexual health services (SHS) in England (uptake has also likely
118 decreased due to the impact of COVID-19 on SHS in-person service delivery)¹². Data on
119 HAV/HBV vaccination uptake among GBMSM in England is also very limited.

120

121 To understand STI/VH vaccination uptake inequalities, we investigated the factors associated
122 with uptake of recommended STI/VH vaccines in the UK among a community-sample of
123 GBMSM.

124

125 **Methods**

126

127 **Study design and Data collection**

128

129 This study used data collected by the 2022 round of the ‘Reducing inequalities in Sexual
130 Health during the mpox outbreak’ (RiiSH-mpox) survey, part of a series of cross-sectional
131 community-based surveys first run in 2017¹³. The RiiSH surveys focus on health and
132 wellbeing, sexual risk behaviours, and use of SHS amongst GBMSM, and have been used to
133 improve understanding of the factors underlying STI trends among GBMSM in the UK^{14,15}.
134 RiiSH-Mpox included questions on these core topics as well as mpox vaccine uptake during

135 the 2022 mpox outbreak. Details of the RiiSH-Mpox methodology have been previously
136 reported¹⁵.

137

138 The RiiSH-Mpox survey was deployed from 24 November-19 December 2022 and included
139 participants that were aged ≥ 16 years, a UK resident, individuals self-identifying as men
140 (cisgender/transgender), transgender women, or gender-diverse individuals assigned male at
141 birth (gender was overlooked in this analysis, 99% self-identified as a cis-male), and
142 individuals who self-reported having had sex with a man in the last year. Participants were
143 recruited through advertisements on social media (Facebook, Instagram, Twitter [now X])
144 and through the geospatial networking application ('dating app') Grindr. Online consent was
145 provided by all participants. Lookback periods for healthcare-related factors and sexual risk
146 behaviours varied from reporting since August 2022 (i.e. last 3-4 months), to ever.

147

148 Due to relatively low numbers of participants who did not self-report being white or
149 gay/homosexual these variables were dichotomised as white or any other ethnic group, and
150 either gay/homosexual or bisexual, respectively.

151

152 **Data analysis**

153

154 **Vaccination uptake**

155

156 To measure uptake and completion levels of vaccination, percentages and 95% confidence
157 intervals (CI) (Clopper-Pearson) were calculated. Uptake was defined as receiving at least
158 one dose of a vaccine and completion as receiving all recommended doses as outlined by the
159 UK vaccination guidance at the time of the survey (2 doses of HAV, HPV or mpox vaccine
160 and 3 HBV vaccine doses).

161

162 Uptake amongst all participants and eligible GBMSM for each vaccine was calculated.
163 Reflecting UK vaccination guidance³, we considered all GBMSM as eligible for HAV and
164 HBV vaccination. HPV vaccination eligibility was considered in GBMSM reporting SHS
165 attendance who were up to and including age 45, given opportunistic vaccination
166 recommendations across SHS. In line with mpox vaccination guidance^{6,10}, mpox vaccination
167 eligibility was considered in those reporting: ≥ 10 physical male sex partners, meeting
168 partners in public sex environments (Sex on premise venues (SOP), cruising grounds or sex
169 parties), having a positive STI test, report of HIV-PrEP or use of chemsex-associated
170 recreational drugs (crystal methamphetamine, mephedrone or gamma-
171 hydroxybutyrate/gamma-butyrolactone). SHS attendance was not considered as part of
172 eligibility for HAV, HBV and mpox vaccination given vaccination availability outside of
173 SHS (e.g. mpox vaccination outreach, general practice and travel clinic availability for VH
174 vaccination).

175

176 To measure the association between uptake of different vaccine types, logistic regression was
177 used to generate the unadjusted (uOR) and adjusted odds ratio (aOR) of receiving at least one

178 dose of a respective vaccine versus also receiving at least one dose of another vaccine
179 (vaccines were compared sequentially, in a pairwise manner). For adjusted analyses, age-
180 group and sexual orientation were considered a priori, and additional factors were added in a
181 forwards stepwise manner based on significant bivariate association and evidence from
182 previous literature^{11,16-19}.

183

184 **Missed vaccination opportunities in those attending sexual health services**

185

186 GBMSM who reported ever having attended an SHS and who met respective proxy
187 vaccination eligibility were considered missed opportunities for vaccination if no vaccination
188 history was reported.

189

190 **Factors associated with vaccination uptake**

191

192 Among all participants irrespective of previous SHS attendance (except those over age 45/
193 those who had not previously attended SHS for HPV vaccination), Pearson's chi-squared test
194 and bivariate logistic regression was used to examine association between sociodemographic,
195 sexual behaviour and health-related factors with vaccination uptake for the HAV, HBV and
196 HPV vaccines, respectively. Analysis of factors associated with vaccination for mpox uptake
197 has been previously reported¹⁵ so was not examined in this analysis. Multivariable adjustment
198 for significant sociodemographic, sexual behaviour and health-related factors, as per methods
199 described above, was applied.

200

201 All analysis was completed using Stata V17.0 (College Station, TX, USA) and all p values
202 below 5% were deemed statistically significant.

203

204

205 **Results**

206 Altogether, 1435 individuals engaged with RiiSH-Mpox survey, of whom 1333 met the
207 inclusion criteria. Of these, half were aged over 45 years, 37% were 30-44 and the remaining
208 13% were 16-29. Almost all self-identified as gay/homosexual (89%) and were of white
209 ethnicity (92%). Most lived in England (86%), 81% were employed, 37% reported at least
210 degree level education, with 48% responding that they were financially comfortable. See
211 Appendix A for sample characteristics.

212

213 **Vaccination Uptake**

214

215 Among all participants, 97% self-reported receiving at least one dose of any STI/VH
216 vaccination. HAV vaccination uptake was 68% (CI:65%-70%, 903/1333) and HBV
217 vaccination was 72% (CI:69%-74, 954/1333). Mpox vaccination uptake among eligible
218 participants was 69% (CI:66%-72%, 601/875), or 52% (CI:49%-55%, 692/1,333) among all

219 GBMSM. In those under age 45 who had ever attended a SHS, HPV vaccination was 73%
220 (CI:69%-76%, 417/574), or 42% (CI:39%-45%, 562/1333) among all participants.

221

222 Receiving one vaccine type was uniformly associated with receiving at least one other
223 (Appendix B). The highest association was found between the HAV and HBV vaccines,
224 individuals who had received one were 12 times more likely to have received at least one
225 dose of the other (aOR:11.98, CI: 9.01-15.92).

226

227 **Vaccine Completion**

228

229 HAV vaccination had the highest completion level amongst participants with 89% (CI:87%-
230 91%, 807/903) of those that had received at least one dose completing the course. Among
231 individuals that initiated HBV vaccination, 75% completed the course (CI:72%-77%,
232 712/954). Of those that had initiated HPV vaccination 84% (CI:80%-88%, 350/ 417) had
233 completed the course and 42% (CI:38%-45%, 288/692) of those that had initiated vaccination
234 for mpox completed the course.

235

236 **Missed vaccination opportunities in those attending sexual health services**

237

238 Missed vaccination opportunities among GBMSM who ever reported SHS attendance history
239 were considered 27% (CI:24-29%) for HAV vaccination, 22% (CI:20-25%) for HBV
240 vaccination, 27% (CI: 26-33%) for HPV vaccination, and 30% (CI: 26-33%) for mpox
241 vaccination.

242

243 **Factors associated with vaccination uptake**

244

245 **Hepatitis A Vaccination uptake**

246

247 There was a bivariate association between HAV uptake and sexual orientation, educational
248 level, and employment status, see Table 2. There were significantly lower odds of HAV
249 vaccination amongst those self-reporting as bisexual (aOR:0.56, (CI:0.4-0.8) vs
250 gay/homosexual), having an education that was below degree-level (aOR:0.7, (CI:0.55-0.9))
251 and being unemployed (aOR:0.69, (CI:0.52-0.92)). There was no evidence of an independent
252 association existing between HAV vaccination uptake and age, however uptake was lower in
253 both the 16-29 age group (aOR:0.54, (CI:0.37-0.78)) and the over 45 age group (aOR:0.74,
254 (CI:0.57-0.97)).

255

256 Sexual behaviours associated with HAV vaccination uptake included self-reported usage of
257 chemsex-related recreational drugs in the previous year (aOR:1.87, (CI:1.16-3.02)), reporting
258 ten or more male physical sex partners (aOR:1.85, (CI:1.4-2.44)), reporting attendance at
259 SOP venues (aOR:1.58, (CI:1.22-2.05)), self-reporting ≥ 10 condomless anal sex (CAS)
260 partners (aOR:1.44, (CI:1.12-1.86)) (all since Aug 2022). Health related factors associated
261 with HAV vaccination uptake included self-reporting being a person living with HIV

262 (PLWHIV) (aOR:2, (CI:1.38-2.88)), receiving a positive STI test in the past year (aOR:1.95,
263 (CI:1.29-2.96)), visiting a SHS in the past year, (aOR:4.31, (CI:3.36-5.54)), STI test in the
264 past year (aOR:3.25, (CI:2.53-4.18)) and reporting usage of HIV-PrEP since December 2021
265 (aOR:3.15, (CI:2.43-4.07)).
266

267 **Hepatitis B Vaccination uptake.**

268
269 There was a bivariate association between HBV uptake and sexual orientation, educational
270 qualifications, and employment status, see Table 3. There were lower odds of HBV
271 vaccination uptake in those self-reporting as bisexual (aOR:0.57, (CI:0.39-0.82)) vs
272 gay/homosexual), having an education that was below degree-level (aOR:0.59, (CI:0.46-
273 0.76)) and being unemployed (aOR:0.71, (CI:0.53-0.96)). There was no evidence of an
274 independent association existing between HBV vaccination uptake and age however uptake
275 was lower in both the 16-29 age group (aOR:0.44, (CI:0.3-0.65)) and the over 45 age group
276 (aOR:0.53, (CI:0.4-0.7)).
277

278 Sexual behaviours associated with uptake included reported usage of chemsex-related
279 recreational drugs in the previous year (aOR:1.75, (CI:1.06-2.88)), reporting ten or more
280 physical male sex partners (aOR:1.89, (CI:1.41-2.53)) reporting attendance at SOP venues
281 (aOR:1.51, (CI:1.15-1.99)), self-reporting ≥ 10 CAS partners (aOR:1.77, (CI:1.37-2.29)) (all
282 since Aug 2022). There were associations with reporting being a PLWHIV (aOR:1.84,
283 (CI:1.26-2.68)), receiving a positive STI test in the past year (aOR:3.17, (CI:1.9-5.29)),
284 visiting a SHS in the past year, (aOR:5.33, (CI:4.1-6.93)), having an STI test in the past year
285 (aOR:4.29, (CI:3.31-5.58)) and reporting usage of HIV-PrEP since Dec 2021 (aOR:4.68,
286 (CI:3.51-6.26)).
287

289 **HPV vaccination uptake**

290
291 Among eligible individuals the only sociodemographic factors found to have an association
292 with HPV vaccination uptake were being in the 16-29 (younger) age-category (aOR:0.62,
293 (CI:0.43-0.89 vs those aged 30-44)) and having an education below degree-level (aOR:0.55,
294 (CI:0.39-0.78)), see Table 4.
295

296 The sexual behaviours that were associated with HPV vaccination uptake include usage of
297 chemsex-related drugs in the previous year (aOR:1.92, (CI:1.01-3.63)), reporting ten or more
298 physical male sex partners (aOR:3.85, (CI:1.77-8.37)) reporting attendance at SOP venues
299 (aOR:1.84, (CI:1.26-2.67)), self-reporting ≥ 10 CAS partners (aOR:4.27, (CI:2.38-7.65)) (all
300 since August 2022). There were increased odds of HPV vaccination in a multivariable model
301 amongst those reporting being a PLWHIV (aOR:3.3, (CI:1.7-6.39)), receiving a positive STI
302 test in the past year (aOR:7.77, (CI:3.5-17.28)), visiting a SHS in the past year (aOR:14.3,
303 (CI:9.51-21.51)), STI test in the past year (aOR:7.74, (CI:5.14-11.65)) and reporting usage of
304 HIV-PrEP since December 2021 (aOR:4.12, (aOR:8.99, (CI:5.97-13.53))).

305

306

307 Discussion

308 Analyses of a large, community-based survey of GBMSM in the UK show that vaccination
309 uptake was high but far from universal for all targeted vaccinations, with uptake at around
310 two-thirds across each of the STI/VH vaccinations considered. In GBMSM attending SHS,
311 approximately a quarter were considered potential missed opportunities for vaccination
312 across each vaccine type. There was highly correlated uptake between different vaccines and
313 similar sociodemographic, behavioural and SHS use factors were associated with uptake of
314 each STI/VH vaccine. This provides an important insight into HAV, HBV and HPV
315 vaccination uptake amongst GBMSM for which there is limited uptake data in the UK²¹.

316 The sociodemographic factors identified in this study found to commonly be associated with
317 lower vaccination uptake were younger age, self-identifying as bisexual, and markers of
318 lower financial or social capital such as an education below degree-level or being
319 unemployed. Vaccination uptake was higher amongst those reporting sexual behaviour which
320 increases risk of STI transmission, and relatedly, in those reporting recent SHS use (greater
321 sexual behaviour is often associated with SHS utilisation²⁰); indicating that those who are
322 most at need of vaccines are receiving them. This mirrors findings of a previous analysis of
323 mpox vaccination uptake¹⁵. Vaccine completion ranged from 42% for mpox to 89% for
324 HAV. The lower completion rate for the mpox vaccination is likely due to the recency of
325 implementation of the vaccination in response to the outbreak in 2022, as well as the fact that
326 the offer of second doses only commenced 2-3 months prior to the survey¹⁰.

327 The lower odds of vaccination amongst younger age groups has previously been reported in
328 other studies assessing HBV and HPV vaccination^{16,19,21}. Gay self-identification, higher
329 levels of education and employment were also consistently found to be linked with higher
330 vaccination uptake amongst GBMSM, including both HBV and HPV vaccinations^{16,18,21}.
331 Young people and bisexual/straight-identifying GBMSM have been identified as groups that
332 have a higher sexual risk and a lower SHS engagement²²⁻²⁴. Promotion focused on bisexual
333 men is important to reduce the burden of these vaccine preventable STI/VHs amongst
334 GBMSM, but also potentially amongst women²⁵.

335 There is also a consistent association between higher vaccination uptake and SHS usage
336 (although HAV/HBV vaccines are also administered outside of SHS). Previous research has
337 found that GBMSM are not actively seeking out vaccines such as the HPV vaccine^{11,17} and
338 that vaccination for HPV is reliant on recommendation by clinicians^{26,27}. It follows that to
339 become aware of, and to be identified as a candidate for vaccination, they must be attending
340 SHSs, (HPV vaccination is targeted to GBMSM attending SHS only). This association has
341 been identified previously with one study finding that 90.9% of GBMSM reporting HPV
342 vaccination had attended a SHS in the previous year²⁸ (86% in this sample).

343

344 Those with markers of lower financial or social capital reported lower vaccination uptake,
345 indicating that health inequalities faced by GBMSM are exacerbated amongst those who
346 already experience inequity. The effects of marginalisation may be compounded, and this
347 requires an intersectional approach to understanding these groups and how to target them
348 effectively. Understanding their behaviour and whether they require changes in policy and
349 tailored interventions to increase their engagement with SHS, and subsequently uptake of
350 STI/VH vaccinations, is needed. This could be through health-promotion messaging such as
351 community outreach programmes and media-based advertisements to reach those who may
352 not normally access SHS. One means may be through encouraging online SHS²⁹ to identify
353 potential vaccination candidates, but this does require online services that are well-integrated
354 with physical SHS and have good signposting for GBMSM, as vaccination requires
355 attendance at a physical venue.

356 Vaccine completion is also incredibly important to confer the maximum protection against
357 infection, amongst this sample many of those that initiated vaccination completed the course
358 of vaccination. One previous study assessing incomplete vaccination amongst GBMSM in
359 England found that the most common reason for not receiving additional vaccine doses was
360 because they were unaware when their next dose was due²⁶. This indicates that vaccine
361 completion requires additional or alternative promotion to encourage that those who receive
362 their initial dose will continue to receive additional vaccine doses.

363 This study has limitations due to the cross-sectional methodology used. For example, there
364 may have been recall error as vaccination was self-reported. Also, participants' behaviours
365 may have changed, and chronology of vaccination relative to behaviour cannot be ascertained
366 (except vaccination for mpox which only became established June 2022¹⁰). There may also
367 be a degree of misclassification bias by retrospectively applying eligibility criteria to
368 participants as their behaviours may have changed over time.

369 Due to the questions regarding vaccination which fell into the 'ever' lookback period, it is
370 impossible to know when vaccination occurred, which could explain high association
371 between HAV and HBV vaccination due to combined packaging of the HAV and HBV
372 vaccination or administration of the combined (HAV/HBV) Twinrix vaccine.

373 There are also limitations based on the participants' demographics with lower response
374 numbers from young people and people who did not self-describe as white. This necessitated
375 dichotomising variables, limiting the quality of these findings for minority groups who also
376 have an increased burden of STIs^{2,30,31}, using dichotomised measures limits this study's
377 ability to assess inequalities in vaccine access by ethnicity or gender identity. There is also
378 potential participation bias, for example the sample appears to be more health conscious than
379 the general GBMSM population. For instance, HPV vaccine uptake within the eligible
380 sample was 65% compared to 34% of GBMSM nationally¹². This sample also excludes
381 GBMSM not using the applications that this survey was advertised on. However, unlike

382 previous studies^{28,32} which often focus on those attending SHS, the target population for this
383 study was the GBMSM community more broadly.

384 Improving uptake is dependent on understanding barriers faced by GBMSM which limit
385 vaccination uptake. Within the UK, awareness of factors affecting uptake (especially as the
386 JCVI has advised routine implementation of opportunistic vaccination for mpox³³ and
387 gonorrhoea [the latter using 4CMenB vaccination³⁴]), will help inform practice and health
388 promotion that aligns with NHS³⁵ and UKHSA³⁶ health equity goals. In an international
389 context, these results could raise awareness of potential limitations in vaccination uptake due
390 to service provision differences and sociodemographic factors in equivalent and future
391 GBMSM-selective vaccination programmes.

392

393 References

394

- 395 1. Blondeel K, Say L, Chou D, et al. Evidence and knowledge gaps on the disease burden
396 in sexual and gender minorities: A review of systematic reviews. *International Journal*
397 *for Equity in Health*; 15. Epub ahead of print 2016. DOI: 10.1186/s12939-016-0304-1.
- 398 2. Mohammed H, Blomquist P, Ogaz D, et al. 100 Years of STIs in the UK: A review of
399 national surveillance data. *Sexually Transmitted Infections*; 94. Epub ahead of print
400 2018. DOI: 10.1136/sextrans-2017-053273.
- 401 3. UKHSA. *Chapter 17-Hepatitis A Hepatitis A The disease*, www.hps.scot.nhs.uk (2022).
- 402 4. UKHSA. *The Green Book on Immunisation - Chapter 18 Hepatitis B*,
403 <https://www.gov.uk/government/publications/national-antenatal-infections-> (2022).
- 404 5. UKHSA. *Chapter 18a-Human papillomavirus (HPV) Human papillomavirus (HPV)*
405 *Human papillomavirus (HPV)*. 2023.
- 406 6. UKHSA. *Green Book Chapter 29 Smallpox and monkeypox*,
407 <https://products.mhra.gov.uk/search/?search=IMVANEX> (2022).
- 408 7. Public Health England. Hepatitis B: the green book, chapter 18. *Immunisation against*
409 *infectious disease*.
- 410 8. UK Health Security Agency. *Immunisation against infectious disease*,
411 [https://www.gov.uk/government/publications/immunisation-against-infectious-](https://www.gov.uk/government/publications/immunisation-against-infectious-disease-the-green-book-front-cover-and-contents-page)
412 *disease-the-green-book-front-cover-and-contents-page* (2021, accessed 22 December
413 2023).
- 414 9. Szymonowicz KA, Chen J. Biological and clinical aspects of HPV-related cancers.
415 *Cancer Biology and Medicine*; 17. Epub ahead of print 2020. DOI:
416 10.20892/j.issn.2095-3941.2020.0370.
- 417 10. Department of Health and Social Care. *Mpox (monkeypox) outbreak: vaccination*
418 *strategy*, [https://www.gov.uk/guidance/monkeypox-outbreak-vaccination-](https://www.gov.uk/guidance/monkeypox-outbreak-vaccination-strategy)
419 *strategy*Guidance (2022).
- 420 11. Nadarzynski T, Smith H, Richardson D, et al. Men who have sex with men who do not
421 access sexual health clinics nor disclose sexual orientation are unlikely to receive the
422 HPV vaccine in the UK. *Vaccine*; 36. Epub ahead of print 2018. DOI:
423 10.1016/j.vaccine.2018.06.075.
- 424 12. PHE. *Human papillomavirus (HPV) vaccination uptake in gay, bisexual and other men*
425 *who have sex with men (MSM)*. 2019.
- 426 13. Wayal S, Reid D, Weatherburn P, et al. Association between knowledge, risk
427 behaviours, and testing for sexually transmitted infections among men who have sex
428 with men: findings from a large online survey in the United Kingdom. *HIV Med*; 20.
429 Epub ahead of print 2019. DOI: 10.1111/hiv.12753.
- 430 14. Ogaz D, Allen H, Reid D, et al. COVID-19 infection and vaccination uptake in men and
431 gender-diverse people who have sex with men in the UK: analyses of a large, online
432 community cross-sectional survey (RiiSH-COVID) undertaken November–December
433 2021. *BMC Public Health*; 23. Epub ahead of print 2023. DOI: 10.1186/s12889-023-
434 15779-5.
- 435 15. Ogaz D, Enayat Q, Phillips D, et al. O14 Mpox diagnosis history, behavioural risk
436 modification, and vaccination uptake in gay, bisexual, and other men who have sex
437 with men in the UK: findings from a large, online community survey (RiiSH-Mpox)

- 438 undertaken December 2022. 2023. Epub ahead of print 2023. DOI: 10.1136/sextrans-
439 bashh-2023.14.
- 440 16. Ortu G, Barret AS, Danis K, et al. Low vaccination coverage for human papillomavirus
441 disease among young men who have sex with men, France, 2019. *Eurosurveillance*;
442 26. Epub ahead of print 2021. DOI: 10.2807/1560-7917.ES.2021.26.50.2001965.
- 443 17. Chin KY, Ekeuku SO, Hamzah MR. The Role of Healthcare Providers in Promoting
444 Human Papillomavirus Vaccines among Men Who Have Sex with Men: A Scoping
445 Review. *Vaccines*; 10. Epub ahead of print 2022. DOI: 10.3390/vaccines10060930.
- 446 18. Vet R, de Wit JBF, Das E. Factors associated with hepatitis B vaccination among men
447 who have sex with men: a systematic review of published research. *International*
448 *Journal of STD and AIDS*; 28. Epub ahead of print 2017. DOI:
449 10.1177/0956462415613726.
- 450 19. Brandl M, Schmidt AJ, Marcus U, et al. Are men who have sex with men in Europe
451 protected from hepatitis B? *Epidemiol Infect.* Epub ahead of print 2020. DOI:
452 10.1017/S0950268820000163.
- 453 20. Tanton C, Geary RS, Clifton S, et al. Sexual health clinic attendance and non-
454 attendance in Britain: findings from the third National Survey of Sexual Attitudes and
455 Lifestyles (Natsal-3). *Sex Transm Infect*; 94. Epub ahead of print 2018. DOI:
456 10.1136/sextrans-2017-053193.
- 457 21. Nadarzynski T, Frost M, Miller D, et al. Vaccine acceptability, uptake and completion
458 amongst men who have sex with men: A systematic review, meta-analysis and
459 theoretical framework. *Vaccine*; 39. Epub ahead of print 2021. DOI:
460 10.1016/j.vaccine.2021.05.013.
- 461 22. Curtis T, Bennett K, Mcdonagh L, et al. P532 The sexual behaviour and health of
462 heterosexual-identifying men who have sex with men: a systematic review. 2019.
463 Epub ahead of print 2019. DOI: 10.1136/sextrans-2019-sti.610.
- 464 23. Brown JRG, Reid D, Howarth AR, et al. Changes in STI and HIV testing and testing need
465 among men who have sex with men during the UK's COVID-19 pandemic response.
466 *Sex Transm Infect*; 99. Epub ahead of print 2023. DOI: 10.1136/sextrans-2022-
467 055429.
- 468 24. Shankar AG, Mandal S, Ijaz S. An outbreak of hepatitis B in men who have sex with
469 men but identify as heterosexual. *Sexually Transmitted Infections*; 92. Epub ahead of
470 print 2016. DOI: 10.1136/sextrans-2015-052490.
- 471 25. Geary RS, Tanton C, Erens B, et al. Sexual identity, attraction and behaviour in Britain:
472 The implications of using different dimensions of sexual orientation to estimate the
473 size of sexual minority populations and inform public health interventions. *PLoS One*;
474 13. Epub ahead of print 2018. DOI: 10.1371/journal.pone.0189607.
- 475 26. Armstrong HL, Scholfield C, Symonds Y, et al. Reasons for incomplete STI vaccination
476 among men who have sex with men in an English sexual health service. *Int J STD AIDS*.
477 Epub ahead of print 2023. DOI: 10.1177/09564624231165078.
- 478 27. Petit B, Epaulard O. Men having sex with men and the HPV vaccine in France: A low
479 vaccine coverage that may be due to its infrequent proposal by physicians. *Vaccine*;
480 38. Epub ahead of print 2020. DOI: 10.1016/j.vaccine.2020.01.049.
- 481 28. Edelstein M, Iyanger N, Hennessy N, et al. Implementation and evaluation of the
482 human papillomavirus (HPV) vaccination pilot for men who have sex with men
483 (MSM), England, April 2016 to March 2017. *Eurosurveillance*; 24. Epub ahead of print
484 2019. DOI: 10.2807/1560-7917.ES.2019.24.8.1800055.

485

- 486 29. Aicken CRH, Estcourt CS, Johnson AM, et al. Use of the internet for sexual health
487 among sexually experienced persons aged 16 to 44 years: Evidence from a nationally
488 representative survey of the british population. *Journal of Medical Internet Research*;
489 18. Epub ahead of print 2016. DOI: 10.2196/JMIR.4373.
- 490 30. Stutterheim SE, Van Dijk M, Wang H, et al. The worldwide burden of HIV in
491 transgender individuals: An updated systematic review and meta-analysis. *PLoS ONE*;
492 16. Epub ahead of print 2021. DOI: 10.1371/journal.pone.0260063.
- 493 31. Kcomt L. Profound health-care discrimination experienced by transgender people:
494 rapid systematic review. *Soc Work Health Care*; 58. Epub ahead of print 2019. DOI:
495 10.1080/00981389.2018.1532941.
- 496 32. Pollock KG, Wallace LA, Wrigglesworth S, et al. HPV vaccine uptake in men who have
497 sex with men in Scotland. *Vaccine*; 37. Epub ahead of print 2019. DOI:
498 10.1016/j.vaccine.2018.11.081.
- 499 33. DHSC. JCVI statement on mpox vaccination as a routine programme,
500 [https://www.gov.uk/government/publications/mpox-vaccination-programme-jcvi-
501 advice-10-november/jcvi-statement-on-mpox-vaccination-as-a-routine-
502 programme#:~:text=The%20JCVI%20advises%20that%20pre,applied%20regardless%2
503 0of%20HIV%20status](https://www.gov.uk/government/publications/mpox-vaccination-programme-jcvi-advice-10-november/jcvi-statement-on-mpox-vaccination-as-a-routine-programme#:~:text=The%20JCVI%20advises%20that%20pre,applied%20regardless%20of%20HIV%20status). (2023, accessed 4 March 2024).
- 504 34. DHSC. *Independent report JCVI advice on the use of meningococcal B vaccination for
505 the prevention of gonorrhoea*,
506 <https://www.gov.uk/government/publications/meningococcal> (2023).
- 507 35. NHS. 2022/23 Priorities and Operational Planning Guidance. *NHS England*.
- 508 36. UKHSA. Achieving more equitable outcomes: UKHSA Health Equity for Health Security
509 Strategy, [https://ukhsa.blog.gov.uk/2023/11/08/achieving-more-equitable-
510 outcomes-ukhsa-health-equity-for-health-security-strategy/](https://ukhsa.blog.gov.uk/2023/11/08/achieving-more-equitable-outcomes-ukhsa-health-equity-for-health-security-strategy/) (2023, accessed 4 March
511 2024).

512

513

	Whole sample *			Eligible Population †			Completion ‡			Missed Opportunity ††		
	n ¶	%	95% confidence interval	n ¶	%	95% confidence interval	n §	%	95% confidence interval	n ††	%	95% confidence interval
Mpox	692	52	49%-55%	601	69	66%-72%	252	42**	38%-46%	249	30	26-33%
HAV	903	68	65%-70%	903	68	65%-70%	807	89	87%-91%	318	27	24-29%
HBV	954	72	69%-74%	954	72	69%-74%	712	75	72%-77%	267	22	20-25%
HPV	562	42	39%-45	429	73	69%-76%	350	84	80%-88%	157	27	24-31%

*Uses all 1333 RiSH-Mpox participants as a denominator † uses all eligible RiSH-MPOX participants as a denominator, we considered all GBMSM as eligible for HAV and HBV vaccination. HPV vaccination eligibility was GBMSM reporting SHS attendance under the age of 46, mpox vaccination eligibility was considered in those reporting: ≥10 physical male sex partners, meeting partners in public sex environments (Sex on premise venues (SOP), cruising grounds or sex parties), having a positive STI test, report of PrEP or use of chemsex-associated recreational drugs (crystal methamphetamine, mephedrone or gamma-hydroxybutyrate/gamma-butyrolactone). ‡ Completion is reported as the percentage of those that received the first dose that self-reported completing the vaccine course ¶ Participants with self-reported uptake of ≥1 vaccine dose(s) § Participants with self-reported completion of that respective vaccine course, 2 doses of HAV, HPV Mpox and 3 doses of HBV ** Low completion in vaccination for Mpox may be due to recency of vaccine programme implementation ††N is all individuals who have previously attended SHS and are eligible for that particular vaccine, Mpox - 845, HAV/HBV - 1195 and HPV - 574. †† number of individuals who have not been vaccinated despite eligibility and SHS attendance. Note, for HAV and HBV vaccination uptake, the whole sample and eligible populations are the same.

Table 2. Sociodemographic characteristics and Health-related and sexual behaviour factors associated with self-reported HAV vaccination uptake among RiSH-Mpox participants

	n total	% of RiSH-Mpox participants	n of HAV vaccinated participants *	% of group vaccinated	% of HAV vaccinated people	uOR **	95% confidence interval	P	aOR §	95% confidence interval	P
Sociodemographic Characteristics											
Age-group											
16-29	176	13	101	57	11	0.48	0.34 - 0.69		0.54	0.37 - 0.78	0.570
30-44	486	36	358	74	40	1.00			1.00		
45+	671	50	444	66	49	0.70	0.54 - 0.90	0.570	0.74	0.57 - 0.97	
Sexual orientation											
Gay/ homosexual	1187	89	823	69	91	1.00			1.00		
Bisexual †	146	11	80	55	9	0.54	0.38 - 0.76	<0.001	0.56	0.40 - 0.80	0.001
Ethnicity											
White	1223	92	832	68	92	1.00			1.00		
Other	110	8	71	65	8	0.86	0.57 - 1.29	0.454	0.90	0.59 - 1.37	0.610
Country of Birth											
UK	1113	83	756	68	84	1.00			1.00		
Other	220	17	147	67	16	0.95	0.70 - 1.29	0.748	0.91	0.66 - 1.26	0.586
Country of Residence											
England	1148	86	779	68	86	1.00			1.00		
Rest of UK	185	14	124	67	14	0.96	0.69 - 1.34	0.823	0.98	0.70 - 1.37	0.904
Educational level											
Degree level or higher	495	37	594	71	66	1.00			1.00		
Below degree level	838	63	309	62	34	0.68	0.54 - 0.86	0.001	0.70	0.55 - 0.90	0.050
Employment											
Currently Employed	1074	19	749	70	83	1.00			1.00		
Not Employed	259	81	154	59	17	0.64	0.48 - 0.84	0.002	0.69	0.52 - 0.92	0.012
Household Composition											
Alone	506	38	552	67	61	1.00			1.00		
With Others	827	62	351	69	39	0.87	0.70 - 1.12	0.321	0.88	0.69 - 1.12	0.307
Relationship Status											
Relationship	591	44	510	86	56	1.00			1.00		
Single	742	56	393	53	44	1.11	0.88 - 1.40	0.870	1.08	0.85 - 1.37	0.540
Comfortable Financial Status											
Yes ††	693	52	453	65	50	1.00			1.00		
No	640	48	450	70	50	0.80	0.63 - 1.00	0.054	0.93	0.73 - 1.18	0.551
Health-related factors											
HIV Status											
Negative/ Unknown	1131	85	744	66	82	1.00			1.00		
PLWHIV	202	15	159	79	18	1.92	1.34 - 2.75	<0.001	2.00	1.38 - 2.88	<0.001
MPOX-related behaviour modification ¶											
No	626	47	412	66	46	1.00			1.00		
Yes	707	53	491	69	54	1.18	0.94 - 1.49	0.157	1.11	0.88 - 1.42	0.355
STI Positive Test											
No	1177	70	778	66	86	1.00			1.00		
Yes	156	30	125	80	14	3.38	2.63 - 4.35	<0.001	1.95	1.29 - 2.96	0.002
Visited SHC in past year											
No	478	36	221	46	24	1.00			1.00		
Yes	855	64	682	80	76	4.58	3.59 - 5.86	<0.001	4.31	3.36 - 5.54	<0.001
STI test in past year											
No	405	30	196	48	22	3.41			1.00		
Yes	928	70	707	76	78	1.00	2.67 - 4.37	<0.001	3.25	2.53 - 4.18	<0.001
PrEP Use in Past Year											
No	734	55	415	57	46	1.00			1.00		
Yes	599	45	488	81	54	3.38	2.63 - 4.35	<0.001	3.15	2.43 - 4.07	<0.001
Sexual behaviours											
Usage of chemsex-related drugs in the previous year											
No	1222	92	815	67	90	1.00			1.00		
Yes	111	8	88	79	10	1.91	1.19 - 3.07	0.007	1.87	1.16 - 3.02	0.010
Number of Male Physical Sex Partners											
none	100	8	64	64	7	1.00			1.00		
1	180	14	93	52	10	0.60	0.36 - 0.99		0.59	0.35 - 0.98	<0.001
2 to 4	389	29	256	66	28	1.08	0.68 - 1.71		1.05	0.66 - 1.68	
5 to 9	280	21	192	69	21	1.23	0.76 - 1.98		1.17	0.72 - 1.90	
10+	384	29	298	78	33	1.95	1.21 - 3.13	0.006	1.78	1.10 - 2.88	
reported use of SOP venues in the lookback period											
No	888	67	568	64	63	1.00			1.00		
Yes	445	33	335	75	37	1.72	1.33 - 2.21	<0.001	1.58	1.22 - 2.05	<0.001
Number of CAS partners in the lookback period (since Dec 2021)											
none	401	30	245	61	27	1.00			1.00		
1	263	20	159	60	18	0.97	0.71 - 1.34		0.94	0.68 - 1.29	<0.001
2 to 4	315	24	219	70	24	1.45	1.06 - 1.99		1.42	1.03 - 1.95	
5 to 9	146	11	118	81	13	2.68	1.70 - 4.24		2.42	1.52 - 3.85	
10+	208	16	162	78	18	2.24	1.53 - 3.29	<0.001	2.11	1.42 - 3.10	

* Participants with self-reported uptake of ≥ 1 HAV vaccine dose(s). † Includes those identifying as bisexual, straight, or another way. †† Top two quartiles ("I am comfortable"/"I am very comfortable" from the question, "How would you best describe your current financial situation"). ¶ Behaviour modification includes self-report of any of the following from May 2022: fewer sexual partners, reduced visits to sex on premises venues or PSE (i.e. cruising grounds), and avoiding: all sex, condomless anal sex, skin-to-skin contact, or visiting clubs or crowds. § Adjusted for age-group, ethnicity, sexual orientation, educational qualifications, employment, and financial situation. ** uOR=Unadjusted odds ratio. aOR=adjusted odds ratio.

Table 3. Sociodemographic characteristics and Health-related and sexual behaviour factors associated with self-reported HBV vaccination uptake among RiSH-Mpox participants

	n total	% of RiSH-Mpox participants	n of HBV vaccinated participants *	% of group vaccinated	% of HBV vaccinated people	uOR **	95% confidence interval	P	aOR †	95% confidence interval	P
Sociodemographic Characteristics											
Age-group											
16-29	176	13	110	63	12	0.40	0.27 - 0.58		0.44	0.30 - 0.65	0.343
30-44	486	36	392	81	41	1.00			1.00		
45+	671	50	452	67	47	0.49	0.38 - 0.65	0.343	0.53	0.40 - 0.70	
Sexual orientation											
Gay/ homosexual	1187	89	866	73	91	1.00			1.00		
Bisexual †	146	11	88	60	9	0.56	0.39 - 0.80	0.002	0.57	0.39 - 0.82	0.002
Ethnicity											
White	1223	92	872	71	91	1.00			1.00		
Other	110	8	82	75	9	1.12	0.75 - 1.84	0.720	1.17	0.74 - 1.86	0.501
Country of Birth											
UK	1113	83	796	72	83	1.00			1.00		
Other	220	17	158	72	17	1.01	0.74 - 1.40	0.928	0.88	0.63 - 1.24	0.469
Country of Residence											
England	1148	86	824	72	86	1.00			1.00		
Rest of UK	185	14	130	70	14	1.01	0.74 - 1.40	0.928	0.95	0.67 - 1.35	0.770
Educational level											
Degree level or higher	495	37	638	76	67	1.00			1.00		
Below degree level	838	63	316	64	33	0.55	0.43 - 0.71	<0.001	0.59	0.46 - 0.76	<0.001
Employment											
Currently Employed	1074	19	790	74	83	1.00			1.00		
Not Employed	259	81	164	63	17	0.55	0.43 - 0.71	<0.001	0.71	0.53 - 0.96	0.026
Household Composition											
Alone	506	38	370	73	39	1.00			1.00		
With Others	827	62	584	71	61	0.88	0.69 - 1.13	0.325	0.85	0.66 - 1.09	0.195
Relationship Status											
Relationship	591	44	539	91	56	1.00			1.00		
Single	742	56	415	56	44	1.13	0.89 - 1.43	0.330	1.12	0.88 - 1.44	0.360
Comfortable Financial Status											
Yes ††	693	52	482	70	51	1.00			1.00		
No	640	48	472	74	49	0.70	0.55 - 0.89	0.004	0.82	0.64 - 1.06	0.122
Health-related factors											
HIV Status											
Negative/ Unknown	1131	85	793	70	83	1.00			1.00		
PLWHIV	202	15	161	80	17	1.67	1.16 - 2.41	0.006	1.84	1.26 - 2.68	0.001
MPOX-related behaviour modification ††											
No	626	47	434	69	45	1.00			1.00		
Yes	707	53	520	74	55	1.23	0.97 - 1.56	0.088	1.14	0.90 - 1.46	0.281
STI Positive Test											
No	1177	70	816	69	86	1.00			1.00		
Yes	156	30	138	88	14	3.39	2.04 - 5.63	<0.001	3.17	1.90 - 5.29	<0.001
Visited SHC in past year											
No	478	36	232	49	24	1.00			1.00		
Yes	855	64	722	84	76	5.76	4.45 - 7.45	<0.001	5.33	4.10 - 6.93	<0.001
STI test in past year											
No	405	30	198	49	21	1.00			1.00		
Yes	928	70	756	81	79	4.60	3.56 - 5.93	<0.001	4.29	3.31 - 5.58	<0.001
PrEP Use in Past Year											
No	734	55	428	58	45	1.00			1.00		
Yes	599	45	526	88	55	5.15	3.87 - 6.69	<0.001	4.68	3.51 - 6.26	<0.001
Sexual behaviours											
Usage of chemsex-related drugs in the previous year											
No	1222	92	864	71	91	1.00			1.00		
Yes	111	8	90	81	9	1.78	1.09 - 2.90	0.022	1.75	1.06 - 2.88	0.028
Number of Male Physical Sex Partners											
none	100	8	64	64	7	1.00			1.00		
1	180	14	103	57	11	0.75	0.45 - 1.25		0.71	0.43 - 1.19	<0.001
2 to 4	389	29	268	69	28	1.25	0.79 - 1.98		1.16	0.72 - 1.86	
5 to 9	280	21	208	74	22	1.63	1.00 - 2.65		2.51	0.92 - 2.48	
10+	384	29	311	81	33	2.40	1.48 - 3.88	<0.001	2.10	1.28 - 3.44	
reported use of SOP venues in the lookback period											
No	888	67	606	68	64	1.00			1.00		
Yes	445	33	348	78	36	1.67	1.28 - 2.18	<0.001	1.51	1.15 - 1.99	0.003
Number of CAS partners in the lookback period (since Dec 2021)											
none	401	30	82	20	9	1.00			1.00		
1	263	20	177	67	19	1.23	0.89 - 1.71		1.19	0.85 - 1.67	0.000
2 to 4	315	24	237	75	25	1.82	1.31 - 2.52		1.83	1.31 - 2.56	
5 to 9	146	11	115	79	12	2.22	1.42 - 3.46		2.02	1.28 - 3.18	
10+	208	16	174	84	18	3.06	2.01 - 4.65	0.000	2.91	1.89 - 4.47	

* Participants with self-reported uptake of ≥1 HBV vaccine dose(s). † Includes those identifying as bisexual, straight, or another way. †† Top two quartiles ("I am comfortable"/"I am very comfortable" from the question, "How would you best describe your current financial situation". ‡ Behaviour modification includes self-report of any of the following from May 2022: fewer sexual partners, reduced visits to sex on premises venues or PSE (i.e. cruising grounds), and avoiding: all sex, condomless anal sex, skin-to-skin contact, or visiting clubs or crowds. § Adjusted for age-group, ethnicity, sexual orientation, educational qualifications, employment, and financial situation. ** uOR=Unadjusted odds ratio. aOR=adjusted odds ratio.

Table 4. Sociodemographic characteristics and Health-related and sexual behaviour factors associated with self-reported HPV vaccination uptake among RiSH-Mpox participants below 45

	n total	% of RiSH-Mpox participants 45+	n of HPV vaccinated participants *	% of group vaccinated	% of HPV vaccinated people	uOR **	95% confidence interval	P	aOR §	95% confidence interval	P
Sociodemographic Characteristics											
Age-group											
16-29	176	27	95	54	22	0.53	0.38 - 0.76	<0.001	0.62	0.43 - 0.89	0.011
30-44	486	73	334	69	78	1.00			1.00		
Sexual orientation											
Gay/ homosexual	579	87	385	66	90	1.00			1.00		
Bisexual †	83	13	44	53	10	0.57	0.36 - 0.90	0.017	0.67	0.41 - 1.08	0.100
Ethnicity											
White	589	89	42	7	10	1.00			1.00		
Other	73	11	387	530	90	0.71	0.43 - 1.16	0.169	0.80	0.47 - 1.35	0.399
Country of Birth											
UK	589	89	93	16	22	1			1.00		
Other	132	20	336	255	78	1.38	0.91 - 2.08	0.130	1.32	0.85 - 2.05	0.223
Country of Residence											
England	565	85	367	65	86	1.00			1.00		
Rest of UK	97	15	62	64	14	0.96	0.61 - 1.50	0.130	0.99	0.62 - 1.58	0.966
Educational level											
Degree level or higher	437	66	124	28	29	1.00			1.00		
Below degree level	225	34	305	136	71	0.53	0.38 - 0.74	<0.001	0.55	0.39 - 0.78	0.001
Employment											
Currently Employed	572	86	385	67	90	1.00			1.00		
Not Employed	90	14	44	49	10	0.47	0.30 - 0.73	0.001	0.62	0.38 - 1.00	0.051
Household Composition											
Alone	221	33	156	71	36	1.00			1.00		
With Others	443	67	273	62	64	0.47	0.30 - 0.73	0.028	0.70	0.99 - 1.00	0.051
Relationship Status											
Single	343	52	213	62	50	1.00			1.00		
Relationship	319	48	216	68	50	0.85	0.62 - 1.17	0.307	1.39	0.98 - 1.95	0.059
Comfortable Financial Status											
Yes ††	353	53	217	61	51	1.00			1.00		
No	309	47	212	69	49	0.73	0.53 - 1.01	0.055	0.91	0.65 - 1.29	0.603
Health-related factors											
HIV Status											
Negative/ Unknown	584	88	363	62	85	1.00			1.00		
PLWHIV	78	12	66	85	15	3.35	1.77 - 6.33	<0.001	3.30	1.70 - 6.39	0.059
MPOX-related behaviour modification ¶											
No	329	50	203	62	47	1.00			1.00		
Yes	333	50	226	68	53	1.31	0.95 - 1.81	0.097	1.17	0.83 - 1.64	0.368
STI Positive Test											
No	568	86	342	60	80	1.00			1.00		
Yes	94	14	87	93	20	8.21	3.73 - 18.06	<0.001	7.77	3.50 - 17.28	<0.001
Visited SHC in past year											
No	227	34	62	27	14	1.00			1.00		
Yes	435	66	367	84	86	14.36	9.72 - 21.22	<0.001	14.30	9.51 - 21.51	<0.001
STI test in past year											
No	165	25	47	28	11	1.00			1.00		
Yes	497	75	382	77	89	8.34	9.72 - 21.22	<0.001	7.74	5.14 - 11.65	<0.001
PrEP Use in Past Year											
No	341	52	148	43	34	1.00			1.00		
Yes	321	48	281	88	66	9.16	6.18 - 13.59	<0.001	8.99	5.97 - 13.53	<0.001
Sexual behaviours											
Usage of chemsex-related drugs in the previous year											
No	601	91	382	64	89	1.00			1.00		
Yes	61	9	47	77	11	1.93	1.04 - 3.58	0.038	1.92	1.01 - 3.63	0.047
Number of Male Physical Sex Partners											
None	34	5	16	47	4	1.00			1.00		
1	88	13	39	44	9	0.90	0.41 - 1.98		0.85	0.38 - 1.92	<0.001
2 to 4	200	30	120	60	28	1.69	0.81 - 3.50		1.63	0.77 - 3.46	
5 to 9	135	20	90	67	21	2.25	1.05 - 4.82		2.12	0.97 - 4.63	
10+	205	31	164	80	38	4.50	2.11 - 9.58		3.85	1.77 - 8.37	
reported use of SOP venues in the lookback period											
No	442	67	262	59	61	1.00			1.00		
Yes	220	33	167	76	39	2.17	1.51 - 3.11	<0.001	1.84	1.26 - 2.67	0.001
Number of CAS partners in the lookback period (since Dec 2021)											
None	172	26	87	51	20	1.00			1.00		
1	138	21	74	54	17	1.13	0.72 - 1.77		1.03	0.65 - 1.64	<0.001
2 to 4	157	24	110	70	26	2.29	1.45 - 3.60		2.19	1.37 - 3.50	
5 to 9	74	11	57	77	13	2.28	1.77 - 6.08		2.74	1.45 - 5.16	
10+	121	18	101	83	24	4.93	2.80 - 8.68	<0.001	4.27	2.38 - 7.65	

* Participants with self-reported uptake of ≥1 HPV vaccine dose(s) in those under 45 years. † Includes those identifying as bisexual, straight, or another way. †† Top two quartiles ("I am comfortable"/"I am very comfortable" from the question, "How would you best describe your current financial situation". ¶ Behaviour modification includes self-report of any of the following from May 2022: fewer sexual partners, reduced visits to sex on premises venues or PSE (i.e. cruising grounds), and avoiding: all sex, condomless anal sex, skin-to-skin contact, or visiting clubs or crowds. § Adjusted for age-group, ethnicity, sexual orientation, educational qualifications, employment, and financial situation. ** uOR=Unadjusted odds ratio. aOR=adjusted odds ratio.

Appendix A. Sociodemographic, Health-related and sexual behaviour characteristics of those who self-reported ≥1 dose of the Mpx, HAV, HBV and HPV vaccines amongst RiSH-Mpx participant										
	n total	% of RiSH-Mpx participants	n of mpx vaccinated participants	% of MPOX vaccinated people	n of HAV vaccinated participants	% of HAV vaccinated people	n of HBV vaccinated participants	% of HBV vaccinated people	n of HPV vaccinated participants	% of HPV vaccinated people
Sociodemographic Characteristics										
Age-group										
16-29	176	13	78	11	101	11	110	12	95	17
30-44	486	36	263	38	358	40	392	41	334	59
45+	671	50	351	51	444	49	452	47	133	24
Sexual orientation										
Gay/ homosexual	1187	89	645	93	823	91	866	91	509	91
Bisexual *	146	11	47	7	80	9	88	9	53	9
Ethnicity										
White	1223	92	635	92	832	92	872	91	512	91
Other	110	8	57	8	71	8	82	9	50	9
Country of Birth										
UK	1113	83	566	82	756	84	796	83	446	79
Other	220	17	126	18	147	16	158	17	116	21
Country of Residence										
England	1148	86	613	89	779	86	824	86	479	85
Rest of UK	185	14	79	11	124	14	130	14	83	15
Educational level										
Degree level or higher	838	63	199	29	594	66	638	67	394	70
Below degree level	495	37	493	71	309	34	316	33	169	30
Employment										
Currently Employed	1074	19	595	86	749	83	790	83	497	88
Not employed	259	81	97	14	154	17	164	17	65	12
Household Composition										
With others	827	38	515	74	351	39	584	61	342	61
Alone	506	62	278	40	552	61	370	39	220	39
Relationship Status										
In relationship	591	44	320	46	510	56	539	56	291	52
Single	742	56	372	54	393	44	415	44	271	48
Comfortable Financial Status										
Yes	693	52	331	48	453	50	482	51	282	50
No	640	48	361	52	450	50	472	49	280	50
Sexual behaviours										
Usage of chemsex-related drugs in the previous year										
No	1222	92	617	89	815	90	864	91	500	89
Yes	111	8	75	11	88	10	90	9	62	11
Number of Male Physical Sex Partners										
None	100	8	31	4	64	7	64	7	28	5
1	180	14	41	6	93	10	103	11	47	8
2 to 4	389	29	170	25	256	28	268	28	159	28
5 to 9	280	21	180	26	192	21	208	22	119	21
10+	384	29	270	39	298	33	311	33	209	37
reported use of SOP venues in the lookback period										
No	888	67	382	55	568	63	606	64	346	62
Yes	445	33	310	45	335	37	348	36	216	38
Number of CAS partners in the lookback period										
None	401	30	57	8	245	27	82	9	119	21
1	263	20	99	14	159	18	177	19	96	17
2 to 4	315	24	185	27	219	24	237	25	143	25
5 to 9	146	11	109	16	118	13	115	12	78	14
10+	208	16	143	21	162	18	174	18	126	22
Health-related factors										
HIV Status										
Negative/ Unknown	1131	85	575	83	744	82	793	83	461	82
PLWHIV	202	15	117	17	159	18	161	17	101	18
MPOX-related behaviour modification ††										
No	626	47	247	36	412	46	434	45	264	47
Yes	707	53	445	64	491	54	520	55	298	53
STI Positive Test										
No	1177	70	568	82	778	86	816	86	457	81
Yes	156	30	124	18	125	14	138	14	105	19
Visited SHC in past year										
No	478	36	82	12	221	24	232	24	60	11
Yes	855	64	610	88	682	76	722	76	484	86
STI test in past year										
No	405	30	81	12	196	22	198	21	60	11
Yes	928	70	611	88	707	78	756	79	502	89
PrEP Use in Past Year										
No	734	55	228	33	415	46	428	45	201	36
Yes	599	45	464	67	488	54	526	55	361	64

* also includes those identifying straight, or another way. † Top two quartiles ("I am comfortable"/"I am very comfortable" from the question, "How would you best describe your current financial situation". †† Behaviour modification includes self-report of any of the following: fewer sexual partners, reduced visits to sex on premises venues or PSE and avoiding: all sex, condomless anal sex, skin-to-skin contact, or visiting clubs or crowds from May 2022.

Appendix B Vaccine uptake and association between uptake of different STI vaccine types amongst RüSH-Mpox participants											
	n	n receiving both vaccines *	% receiving both vaccines	uOR †	95% confidence interval		P	aOR † †	95% confidence interval		P
Any Vaccine Uptake	1135		97								
Mpox Vaccine uptake											
Mpox	692										
HAV	903	558	62	3.57	2.80	- 4.56	<0.001	3.30	2.57	- 4.25	<0.001
HBV	954	581	61	3.76	2.91	- 4.86	<0.001	3.40	2.61	- 4.42	<0.001
HPV	562	387	69	3.38	2.69	- 4.25	<0.001	4.14	3.16	- 5.42	<0.001
HAV Vaccine Uptake	903		68								
Mpox	692	558	81	3.57	2.80	- 4.56	<0.001	3.30	2.57	- 4.25	<0.001
HAV	903										
HBV	954	794	83	12.29	9.29	- 16.26	<0.001	11.98	9.01	- 15.92	<0.001
HPV	562	490	87	5.90	4.44	- 7.84	<0.001	8.04	5.82	- 11.11	<0.001
HBV Vaccine uptake	954		72								
Mpox	692	581	84	3.76	2.91	- 4.86	<0.001	3.40	2.61	- 4.42	<0.001
HAV	903	794	88	12.29	9.29	- 16.26	<0.001	11.98	9.01	- 15.92	<0.001
HBV	954										
HPV	562	512	91	7.62	5.15	- 10.53	<0.001	9.27	6.51	- 13.21	<0.001
HPV Vaccine Uptake			42								
Mpox	692	387	56	3.38	2.69	- 4.25	<0.001	3.30	2.57	- 4.25	<0.001
HAV	903	490	54	5.90	4.44	- 7.84	<0.001	8.04	5.82	- 11.11	<0.001
HBV	954	512	54	7.62	5.52	- 10.53	<0.001	9.27	6.51	- 13.21	<0.001
HPV	562										

* Participants with self-reported uptake of ≥ 1 vaccine dose of both vaccine types. † uOR=Unadjusted odds ratio. aOR=adjusted odds ratio. † † Adjusted for age-group, sexual orientation, educational level, employment, ethnicity and financial situation.